SEC Form 4 · accession 0000899243-18-001374
MyoKardia Inc · MYOK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph Lambing
Officer — See Remarks
Period of report
Jan 16, 2018
Accepted (ET)
Jan 18, 2018 · 7:51 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001552451
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $52.00 | Jan 16, 2018 | A | 20,800 | A | — | Jan 15, 2028 | Common Stock | 20,800 | 20,800 | D |
| Restricted Stock UnitsF2 | — | Jan 16, 2018 | A | 3,500 | A | — | — | Common Stock | 3,500 | 3,500 | D |
Explanation of responses
- F1The shares underlying the option vest in 48 equal monthly installments from January 1, 2018, so long as the Reporting Person continues to be an employee of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.
- F2Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2018, so that all of the underlying shares shall be vested on January 1, 2022, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer.
Remarks
Senior Vice President, Non-Clinical and Pharmaceutical Development